Applied DNA Q4 revenue down 78% to $780K; net loss widens to $3.6M

BNB PLUS CORP.

Total revenues $780K vs $3.6M YoY; COVID testing contract with CUNY canceled in June 2023.
Gross profit $79K (10% margin) vs $417K (12%) YoY.
Operating loss $4.2M improved slightly from $4.3M; net loss $3.6M vs $665K YoY.
Cash and equivalents $7.2M at Sep 30, 2023, down from $10.8M at Jun 30, 2023.
CEO cites biotherapeutic pivot momentum; GMP capacity expected online H1 2024.

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

BNB PLUS CORP. reported fourth quarter ended September 30, 2023 results: revenue approximately $780 thousand, net income $3.6 million.

Period: fourth quarter ended September 30, 2023
Revenue: approximately $780 thousand
Net income: $3.6 million
Result: reported results

Exact text from the filing

in vitro diagnostics, gene editing/therapy and adoptive cell therapy applications.” Summary Fourth Quarter Fiscal 2023 Financial Results: · Total revenues were approximately $780 thousand for the three-month period September 30, 2023, compared to $3.6 million for the same period in the prior fiscal year. The decrease in revenue of approximately $2.8 million was

View on SEC.gov

51 earnings releases filed in the last 30 days. Browse all earnings releases →

BNB PLUS CORP. filing history →

Source: SEC EDGAR

accession 0001104659-23-124293

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.